SG10202108814VA - Conditionally active biological proteins - Google Patents
Conditionally active biological proteinsInfo
- Publication number
- SG10202108814VA SG10202108814VA SG10202108814VA SG10202108814VA SG10202108814VA SG 10202108814V A SG10202108814V A SG 10202108814VA SG 10202108814V A SG10202108814V A SG 10202108814VA SG 10202108814V A SG10202108814V A SG 10202108814VA SG 10202108814V A SG10202108814V A SG 10202108814VA
- Authority
- SG
- Singapore
- Prior art keywords
- conditionally active
- active biological
- biological proteins
- proteins
- conditionally
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562120312P | 2015-02-24 | 2015-02-24 | |
US201562249907P | 2015-11-02 | 2015-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202108814VA true SG10202108814VA (en) | 2021-09-29 |
Family
ID=56789902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108814VA SG10202108814VA (en) | 2015-02-24 | 2016-02-24 | Conditionally active biological proteins |
SG11201705988UA SG11201705988UA (en) | 2015-02-24 | 2016-02-24 | Conditionally active biological proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705988UA SG11201705988UA (en) | 2015-02-24 | 2016-02-24 | Conditionally active biological proteins |
Country Status (11)
Country | Link |
---|---|
US (3) | US10563194B2 (en) |
EP (1) | EP3262217A4 (en) |
JP (3) | JP7025214B2 (en) |
KR (3) | KR20210096326A (en) |
CN (1) | CN107580603A (en) |
AU (2) | AU2016222830B2 (en) |
CA (2) | CA2977687C (en) |
MX (2) | MX2017010795A (en) |
RU (1) | RU2733658C2 (en) |
SG (2) | SG10202108814VA (en) |
WO (1) | WO2016138071A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3083689T3 (en) | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3 antibodies and methods of use |
US20170260261A1 (en) | 2014-08-28 | 2017-09-14 | Bioatla, Llc | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells |
LT3455261T (en) * | 2016-05-13 | 2022-11-10 | Bioatla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
KR102585956B1 (en) * | 2016-08-31 | 2023-10-05 | 바이오아트라, 인코퍼레이티드 | Conditionally active polypeptides and methods of making them |
CN109923128A (en) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | Administration for being treated with anti-CD20/ AntiCD3 McAb bispecific antibody |
AU2018205629A1 (en) | 2017-01-03 | 2019-07-11 | Bioatla Llc | Protein therapeutics for treatment of senescent cells |
US20230192839A1 (en) * | 2017-04-12 | 2023-06-22 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
JP7473977B2 (en) * | 2018-06-05 | 2024-04-24 | バイオアトラ インコーポレイテッド | Anti-IL22 antibodies, antibody fragments and immunoconjugates thereof and uses thereof |
US20210253702A1 (en) * | 2018-06-14 | 2021-08-19 | Bioatla, Inc. | Multi-specific antibody constructs |
CN111505288B (en) * | 2020-05-15 | 2022-03-01 | 重庆医科大学 | Novel depression biomarker and application thereof |
CN114259460B (en) * | 2020-09-16 | 2024-03-15 | 苏州大学 | Hydrogel composition based on immunoadjuvant and application thereof |
CN118076632A (en) * | 2021-10-19 | 2024-05-24 | 生物蛋白有限公司 | Conditionally active proteins for neurodegenerative diseases |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
JPH05236997A (en) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | Chip for catching polynucleotide |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
AU1124997A (en) * | 1995-11-28 | 1998-06-19 | Johns Hopkins University School Of Medicine, The | Conditionally replicating viral vectors and their use |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
CN1273609A (en) | 1997-08-15 | 2000-11-15 | 希斯克有限公司 | Method and compositions for detection or quantification of nucleic acid species |
DE69833698T2 (en) | 1997-09-11 | 2006-11-16 | Bioventures, Inc., Murfreesboro | Process for the preparation of high density arrays |
US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
ES2303358T3 (en) | 1997-11-03 | 2008-08-01 | Human Genome Sciences, Inc. | VEGI, AN INHIBITOR OF ANGIOGENESIS AND TUMOR GROWTH. |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
JP4199545B2 (en) | 2001-04-27 | 2008-12-17 | ビボキシド オサケユイチア | Method for improving soft tissue adhesion and use of said method for graft preparation |
WO2003105757A2 (en) | 2002-06-12 | 2003-12-24 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
NZ543202A (en) | 2003-05-31 | 2008-04-30 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
ATE477277T1 (en) | 2004-02-16 | 2010-08-15 | Micromet Ag | FEWER IMMUNOGENE BINDING MOLECULES |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP5686953B2 (en) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Compositions comprising cross-species-specific antibodies and uses of the compositions |
CA2633594C (en) | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
NZ569204A (en) | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
KR20080090441A (en) | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Epha2 bite molecules and uses thereof |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
SI2352763T2 (en) | 2008-10-01 | 2022-11-30 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
LT2982696T (en) | 2008-11-07 | 2019-06-10 | Amgen Research (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
JP5774493B2 (en) | 2008-12-31 | 2015-09-09 | メタボリック エクスプローラー | Diol production method |
CN102482347B (en) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | Modified antibody compositions, and methods of making and using thereof |
AU2010222818B2 (en) | 2009-03-09 | 2015-05-14 | Bioatla, Llc | Mirac proteins |
CN106119113A (en) | 2009-04-30 | 2016-11-16 | 基因组股份公司 | For producing the biology of 1,3 butanediols |
WO2011005782A2 (en) | 2009-07-06 | 2011-01-13 | Brigham Young University | Method for pretreatment of cellulosic and lignocellulosic materials for conversion into bioenergy |
ES2701931T3 (en) | 2009-07-17 | 2019-02-26 | Bioatla Llc | Simultaneous and integrated selection and evolution of antibody and protein expression and expression in production hosts |
CA2810668A1 (en) * | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
WO2012177619A2 (en) | 2011-06-22 | 2012-12-27 | Genomatica, Inc. | Microorganisms for producing 1,3-butanediol and methods related thereto |
RU2732151C2 (en) | 2011-09-30 | 2020-09-11 | Чугаи Сейяку Кабусики Кайся | Library of concentration-dependent binding molecules |
EP2822970A1 (en) | 2012-03-08 | 2015-01-14 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
US20140206596A1 (en) | 2013-01-18 | 2014-07-24 | University Of Southern California | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions |
-
2016
- 2016-02-24 AU AU2016222830A patent/AU2016222830B2/en active Active
- 2016-02-24 EP EP16756238.8A patent/EP3262217A4/en active Pending
- 2016-02-24 WO PCT/US2016/019242 patent/WO2016138071A1/en active Application Filing
- 2016-02-24 CA CA2977687A patent/CA2977687C/en active Active
- 2016-02-24 JP JP2017562970A patent/JP7025214B2/en active Active
- 2016-02-24 KR KR1020217024058A patent/KR20210096326A/en not_active IP Right Cessation
- 2016-02-24 SG SG10202108814VA patent/SG10202108814VA/en unknown
- 2016-02-24 CN CN201680012058.5A patent/CN107580603A/en active Pending
- 2016-02-24 US US15/546,883 patent/US10563194B2/en active Active
- 2016-02-24 MX MX2017010795A patent/MX2017010795A/en active IP Right Grant
- 2016-02-24 CA CA3225013A patent/CA3225013A1/en active Pending
- 2016-02-24 KR KR1020237022948A patent/KR20230109773A/en not_active Application Discontinuation
- 2016-02-24 RU RU2017127972A patent/RU2733658C2/en active
- 2016-02-24 KR KR1020177023331A patent/KR102286801B1/en active IP Right Grant
- 2016-02-24 SG SG11201705988UA patent/SG11201705988UA/en unknown
-
2017
- 2017-08-22 MX MX2020011052A patent/MX2020011052A/en unknown
-
2020
- 2020-01-03 US US16/733,358 patent/US11254932B2/en active Active
-
2021
- 2021-05-28 AU AU2021203506A patent/AU2021203506A1/en active Pending
- 2021-11-12 JP JP2021184506A patent/JP2022031720A/en active Pending
-
2022
- 2022-01-11 US US17/573,389 patent/US20220127595A1/en active Pending
-
2023
- 2023-09-26 JP JP2023163210A patent/JP2023182651A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020011052A (en) | 2020-11-06 |
US20200199578A1 (en) | 2020-06-25 |
JP7025214B2 (en) | 2022-02-24 |
SG11201705988UA (en) | 2017-08-30 |
KR102286801B1 (en) | 2021-08-09 |
JP2018513206A (en) | 2018-05-24 |
US10563194B2 (en) | 2020-02-18 |
EP3262217A1 (en) | 2018-01-03 |
KR20210096326A (en) | 2021-08-04 |
RU2017127972A (en) | 2019-03-25 |
CA2977687C (en) | 2024-02-13 |
WO2016138071A1 (en) | 2016-09-01 |
US20190024078A1 (en) | 2019-01-24 |
KR20170117089A (en) | 2017-10-20 |
JP2023182651A (en) | 2023-12-26 |
AU2016222830A1 (en) | 2017-08-10 |
CA3225013A1 (en) | 2016-09-01 |
CN107580603A (en) | 2018-01-12 |
CA2977687A1 (en) | 2016-09-01 |
AU2016222830B2 (en) | 2021-02-25 |
RU2733658C2 (en) | 2020-10-06 |
US20220127595A1 (en) | 2022-04-28 |
EP3262217A4 (en) | 2018-07-18 |
JP2022031720A (en) | 2022-02-22 |
AU2021203506A1 (en) | 2021-06-17 |
KR20230109773A (en) | 2023-07-20 |
MX2017010795A (en) | 2018-04-11 |
RU2017127972A3 (en) | 2019-08-09 |
US11254932B2 (en) | 2022-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202108814VA (en) | Conditionally active biological proteins | |
GB201502305D0 (en) | Protein | |
EP3143138A4 (en) | Conditionally active biological proteins | |
GB201502306D0 (en) | Protein | |
HK1245293A1 (en) | Novel proteins specific for pyoverdine and pyochelin | |
HK1253684A1 (en) | Conditionally active polypeptides | |
PT3531824T (en) | Insecticidal proteins | |
HK1248272A1 (en) | Host cell protein modification | |
GB201515745D0 (en) | Proteins | |
GB201511787D0 (en) | Proteins | |
HUE050893T2 (en) | Protein | |
EP3463414C0 (en) | Protein interfaces | |
GB201415344D0 (en) | Protein | |
GB201608197D0 (en) | Novel proteins | |
PL3099793T3 (en) | Protein | |
GB201513033D0 (en) | Proteins | |
GB201411506D0 (en) | Modified latency associated protein construct | |
GB2558968B (en) | G Proteins | |
SG10201910999TA (en) | Native protein purification technology | |
GB201522610D0 (en) | Protein | |
GB201515744D0 (en) | Proteins | |
GB201515337D0 (en) | Protein Expression | |
GB201503778D0 (en) | Proteins | |
GB201503027D0 (en) | Solid protein supplement | |
GB201414371D0 (en) | Protein modification |